Sahajanand Medical Technologies IPO Details: Date, Price, GMP, Review & How to Apply

Quick Overview

Sahajanand Medical Technologies IPO is a book-built public issue of ₹475.48 crore. The issue is entirely an offer for sale of 1,38,22,116 shares. There is no fresh issue component.

The IPO opens for subscription on 15 October 2026 and closes on 19 October 2026. The allotment is expected to be finalised on 21 October 2026. Subject to completion of allotment and listing formalities, the shares are scheduled to list on NSE and BSE on 23 October 2026.

The price band is ₹327 to ₹344 per share. The lot size is 43 shares, and the minimum retail investment is ₹14,792 at the upper price band.

Since the issue is OFS only, the company will not receive proceeds from the IPO. The proceeds will go to the selling shareholders.

No live GMP value was provided in the available details. Investors should verify updated GMP, subscription and exchange data before making any decision.

Sahajanand Medical Technologies IPO Overview

Sahajanand Medical Technologies Limited is a medical technology company focused on the development, manufacturing and marketing of advanced medical devices.

The company primarily operates in vascular intervention and structural heart intervention. Its product portfolio includes coronary stents, coronary balloons, transcatheter aortic valve implantation devices, occluders, renal stents and peripheral drug-coated balloons.

The IPO is entirely an offer for sale. This means existing shareholders are selling shares through the IPO, and the company’s share capital will not increase because of the issue.

The company’s flagship brands include Supraflex Cruz, Cocoon and Hydra, serving different areas of interventional cardiology.

Investors comparing IPOs with Pre-IPO opportunities can also read Ultra’s guide on Pre-IPO vs IPO.

Because the IPO is entirely an OFS, the company’s pre-issue and post-issue shareholding remains the same at 10,16,46,778 shares.

Sahajanand Medical Technologies IPO GMP

GMP stands for Grey Market Premium. It is the unofficial premium at which IPO shares may trade in the grey market before listing.

For example, if the issue price is ₹344 and the GMP is ₹20, the implied grey market price would be ₹364.

However, GMP is not official and should be used carefully because:

• it is not regulated

• it can change quickly

• it does not guarantee listing gains

• it may not reflect company fundamentals

• it may be influenced by short-term sentiment

No live Sahajanand Medical Technologies IPO GMP value was provided in the available details. Investors should avoid relying only on GMP and should review the RHP, financials, valuation, OFS structure, subscription status and personal suitability before applying.

For a detailed explainer, investors can also read Ultra’s guide on What Is IPO GMP and Why It Can Be Misleading?.

Sahajanand Medical Technologies IPO Subscription Status

No live Sahajanand Medical Technologies IPO subscription status was provided in the available details.

Subscription status usually shows category-wise demand across investor groups such as QIB, NII and retail. It can change throughout the bidding period, especially on the final day.

Investors tracking subscription data should review:

• QIB subscription

• NII subscription

• retail subscription

• total subscription

• final day demand

• subscription relative to valuation and fundamentals

Subscription figures can indicate demand, but they should not be treated as a standalone reason to apply.

About Sahajanand Medical Technologies

Incorporated in October 2001, Sahajanand Medical Technologies Limited is a medical technology company engaged in the development, manufacturing and marketing of technologically advanced medical devices.

The company focuses mainly on vascular intervention and structural heart intervention.

Its product portfolio includes:

• coronary stents

• coronary balloons

• transcatheter aortic valve implantation devices

• occluders

• renal stents

• peripheral drug-coated balloons

The company operates three manufacturing facilities, including two in India and one in Thailand. It is also supported by two R&D centres in India and Thailand.

As of 30 June 2026, the company had:

• 119 patents granted globally

• 78 patent applications in the pipeline

• 5 design registrations in India

Its products were marketed in 77 countries in Fiscal 2026 through direct, hybrid and distributor-led models.

As of 30 June 2026, the company had 1,605 full-time employees, 31 consultants and 707 contract-based employees.

Sahajanand Medical Technologies Business Model

Sahajanand Medical Technologies operates as a medical device manufacturer with a focus on interventional cardiology and related high-barrier segments.

Key Strengths of Sahajanand Medical Technologies

The company’s strengths include:

• technologically advanced medical devices in high-barrier segments

• strong research and development capabilities

• diversified and integrated manufacturing facilities

• global sales and marketing network

• leadership presence in India and key international markets

• patent portfolio and product innovation focus

• M&A and strategic collaboration capabilities

• experienced leadership team backed by reputed institutional investors

These strengths should be evaluated along with regulatory risk, clinical adoption, product concentration, export exposure, competitive intensity and OFS-only issue structure.

Sahajanand Medical Technologies Financials

Sahajanand Medical Technologies reported total income of ₹1,218.73 crore and profit after tax of ₹69.08 crore in FY2026.

According to the provided data, revenue increased by 18%, while PAT rose by 175% between FY2025 and FY2026.

The company’s total income increased from ₹1,035.96 crore in FY2025 to ₹1,218.73 crore in FY2026. PAT increased from ₹25.15 crore to ₹69.08 crore during the same period.

Total borrowing increased from ₹224.96 crore in FY2025 to ₹269.53 crore in FY2026, and stood at ₹320.63 crore as of 30 June 2026.

The company also reported revenue from operations of ₹12,105.04 million in FY2026, compared with ₹10,248.79 million in FY2025 and ₹9,016.04 million in FY2024.

Sahajanand Medical Technologies IPO Valuation

Based on the post-issue share capital of 10,16,46,778 shares, the implied post-issue market capitalisation is approximately:

• ₹3,323.85 crore at the lower price band of ₹327 per share

• ₹3,496.65 crore at the upper price band of ₹344 per share

These calculations are based on the shared data. Investors should verify final issue details, peer comparison, RHP valuation metrics and updated market data before making any decision.

Sahajanand Medical Technologies IPO Review

A practical review should look at the company’s medical device portfolio, R&D capabilities, global presence, profitability growth and OFS-only issue structure.

Positive Factors

Sahajanand Medical Technologies operates in specialised medical device segments such as vascular intervention and structural heart intervention. These are high-barrier categories where product quality, clinical support, regulatory approvals and doctor adoption are important.

The company has a global presence, with products marketed in 77 countries in Fiscal 2026. It also has manufacturing and R&D presence across India and Thailand.

The company’s patent portfolio is also a key strength. As of 30 June 2026, it had 119 patents granted globally and 78 patent applications in the pipeline.

Financially, the company moved from a loss of ₹7.35 crore in FY2024 to PAT of ₹69.08 crore in FY2026. EBITDA also increased from ₹110.05 crore in FY2024 to ₹170.66 crore in FY2026.

Points to Watch

The IPO is entirely an offer for sale. This means the company will not receive fresh proceeds from the issue.

The valuation at the upper price band implies an approximate P/E of 50.6x based on FY2026 PAT. Investors should compare this with peer valuations, growth prospects, margin profile and return metrics.

The business operates in regulated medical device markets. Regulatory approvals, clinical performance, quality standards and product acceptance are critical.

Total borrowing increased from ₹224.96 crore in FY2025 to ₹269.53 crore in FY2026, and further to ₹320.63 crore as of 30 June 2026.

Investors should not rely only on GMP, subscription status or IPO headlines. They should review the RHP, valuation, OFS structure, financials and risk factors carefully.

How to Apply for Sahajanand Medical Technologies IPO

Investors can apply through supported broker platforms using UPI or ASBA.

The general process is:

• Log in to your broker or bank-supported IPO platform.

• Select the issue from the IPO list.

• Choose the investor category and number of lots.

• Enter the bid price or select the cut-off option, if eligible.

• Submit the application.

• Approve the UPI mandate, if applying through UPI.

• Wait for allotment finalisation.

• If allotted, shares will be credited to the demat account before listing.

• Track the scheduled listing on NSE and BSE, subject to completion of allotment and exchange listing formalities.

Retail investors can apply for a minimum of 1 lot, which equals 43 shares and requires ₹14,792 at the upper price band.

Key Risks

1. OFS-Only Issue

The IPO is entirely an offer for sale. The company will not receive any fresh capital from the IPO proceeds.

2. Valuation Risk

At the upper price band, the implied post-issue market capitalisation is approximately ₹3,496.65 crore, with an approximate P/E of 50.6x based on FY2026 PAT. Investors should assess whether this valuation is justified by growth and profitability.

3. Regulatory Risk

Medical device companies operate in regulated markets. Product approvals, compliance requirements, quality standards and regulatory changes may affect business performance.

4. Product and Clinical Adoption Risk

The company’s products depend on clinical acceptance, doctor adoption, hospital usage and patient outcomes. Any adverse product performance issue may affect reputation and demand.

5. Competition Risk

The company competes with domestic and global medical device companies in high-barrier but competitive segments.

6. Borrowing Risk

Total borrowing increased to ₹269.53 crore in FY2026 and ₹320.63 crore as of 30 June 2026. Investors should review the company’s debt profile and repayment obligations.

7. Export and International Market Risk

The company markets products in international markets. Currency movement, regulatory differences, distributor dependency and geopolitical factors may affect performance.

8. GMP and Listing Risk

Grey market premium and subscription trends may change before listing. They should not be treated as guaranteed listing performance indicators.

Final Thoughts

Sahajanand Medical Technologies IPO is a ₹475.48 crore book-built issue with a price band of ₹327 to ₹344 per share. The issue is entirely an offer for sale, which means the company will not receive fresh proceeds from the IPO.

The company operates in the medical technology space, with a focus on vascular intervention and structural heart intervention. Its product portfolio includes coronary stents, coronary balloons, TAVI devices, occluders, renal stents and peripheral drug-coated balloons.

Financially, Sahajanand Medical Technologies reported FY2026 total income of ₹1,218.73 crore and PAT of ₹69.08 crore. Revenue and profitability improved compared with FY2025.

Investors should evaluate the RHP, valuation, OFS-only structure, regulatory risks, medical device adoption, borrowing levels, subscription status, GMP context and personal suitability before applying.

FAQs

1. What is Sahajanand Medical Technologies IPO?

Sahajanand Medical Technologies IPO is a book-built public issue of ₹475.48 crore. The issue is entirely an offer for sale of 1,38,22,116 shares.

2. What is Sahajanand Medical Technologies IPO date?

The issue opens on 15 October 2026 and closes on 19 October 2026.

3. What is Sahajanand Medical Technologies IPO price?

The price band is ₹327 to ₹344 per share.

4. What is Sahajanand Medical Technologies IPO issue size?

The IPO issue size is ₹475.48 crore. The issue is entirely an offer for sale of 1,38,22,116 shares.

5. What is Sahajanand Medical Technologies IPO GMP?

No live GMP value was provided in the available details. GMP is unofficial, volatile and should not be treated as a guaranteed listing gain indicator.

6. What is Sahajanand Medical Technologies share price?

Before listing, the relevant price is the IPO price band of ₹327 to ₹344 per share. After listing, the share price will be discovered on NSE and BSE.

7. What is Sahajanand Medical Technologies share price target?

This article does not provide a share price target. Investors should review company fundamentals, valuation, risks and market conditions before making any decision.

8. What is the lot size for Sahajanand Medical Technologies IPO?

The lot size is 43 shares.

9. What is the minimum investment for retail investors?

The minimum retail investment is ₹14,792 for 1 lot of 43 shares at the upper price band of ₹344 per share.

10. When is the allotment expected?

The allotment is expected to be finalised on 21 October 2026.

11. When will Sahajanand Medical Technologies list?

The shares are scheduled to list on NSE and BSE on 23 October 2026, subject to completion of allotment and exchange listing formalities.

12. Who is the registrar?

MUFG Intime India Pvt. Ltd. is the registrar of the issue.

13. Who is the book running lead manager?

Motilal Oswal Investment Advisors Ltd. is the book running lead manager.

14. Is Sahajanand Medical Technologies IPO a fresh issue or OFS?

The issue is entirely an offer for sale. There is no fresh issue component.

15. Will Sahajanand Medical Technologies receive IPO proceeds?

No. Since the IPO is entirely an OFS, the company will not receive proceeds from the issue. The proceeds will go to selling shareholders.

16. Is Sahajanand Medical Technologies profitable?

Yes. Based on the provided financials, Sahajanand Medical Technologies reported PAT of ₹69.08 crore in FY2026 and ₹25.15 crore in FY2025. It had reported a loss of ₹7.35 crore in FY2024.

17. What does Sahajanand Medical Technologies do?

Sahajanand Medical Technologies develops, manufactures and markets medical devices focused on vascular intervention and structural heart intervention.

18. Should investors apply for Sahajanand Medical Technologies IPO?

Investors should evaluate the RHP, financials, valuation, OFS-only structure, regulatory risks, medical device market risks, subscription status, GMP context and personal suitability before deciding. This article does not provide investment advice or an IPO recommendation.